Poor
Not Aligned
Patient Risk:
High
Summary
Several claims are unsupported by the provided label excerpts, and one claim about route of administration (SC use) is contradicted by the provided label text specifying intravenous injection.
Category Scores
Accurate Statements
The prescription label includes strength information for the injection (2 USP units/mL for the listed presentations).
Supported by Section 3 (Dosage Forms and Strengths): concentrations listed as 2 USP units/mL.
The prescription label describes the product as an injection and includes intravenous injection information.
Supported by Section 11: 'to be administered by intravenous injection.' Also described as 'Heparin Sodium in 0.9% Sodium Chloride Injection' in Section 3.
The dose/potency is expressed in units (USP units of heparin activity).
Supported by Section 3 strengths in USP units per mL and Section 11: potency determined based on 'units of heparin activity.'
Unsupported Statements
Heparin is marketed under multiple brand names depending on the country and whether it is prescribed as injectable (unfractionated heparin) versus other formulations.
Branding/country-variant/multi-formulation discussion is not present in the provided label sections.
In the US, patients may see heparin referred to by brand names such as Heparin Sodium products from different manufacturers.
No manufacturer brand/discussion is present in the provided label sections.
The prescription label typically shows the manufacturer or 'distributed by' line.
No manufacturer/distributed-by line is present in the provided label sections.
Brands of heparin may differ by manufacturer even when the active ingredient is the same.
Not addressed in the provided label sections.
People sometimes search for 'heparin' but mean unfractionated heparin.
Not addressed in labeling; not part of the provided label sections.
Low-molecular-weight heparins (LMWH) are different drugs with different brands.
LMWH is not mentioned in the provided label sections.
LMWH and unfractionated heparin are used for similar clot-prevention purposes.
No LMWH comparison or clot-prevention purpose discussion is present in the provided label sections.
DrugPatentWatch.com tracks drug-related information and may include brand and manufacturer details for heparin products, depending on what is available for the specific product name.
External website/tracking is not addressed in FDA-approved labeling and is not present in the provided label sections.
Contradictions
High
AI Statement
Unfractionated heparin is used as IV/SC injections.
Label Reference
Section 11: 'It is to be administered by intravenous injection.'
Important Omissions
No discussion of the label-supported indication: maintaining catheter patency (Section 1).
Importance:
Moderate
No coverage of provided contraindications (Section 4), boxed warnings (not provided), or other required safety content beyond the excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes a contradictory administration route claim (SC use) despite the provided label specifying intravenous injection. This could contribute to medication administration errors if followed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Contradicted administration route claim (SC) and multiple unsupported brand/manufacturer/external-source statements.
Suggested Improvement
Limit claims to the provided label excerpts (e.g., strength in USP units/mL and that the specified product is administered by intravenous injection) and remove unsupported branding/manufacturer and LMWH-related statements not contained in the label excerpts.